898774-10-2

Basic information

• Product Name: 2',4'-DIFLUORO-3-(2-METHOXYPHENYL)PROPIOPHENONE
• Synonyms: 2',4'-DIFLUORO-3-(2-METHOXYPHENYL)PROPIOPHENONE
• CAS NO: 898774-10-2
• Molecular Formula: C16H14F2O2
• Molecular Weight: 276.28
• Mol File: 898774-10-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 387.3°C at 760 mmHg
• Flash Point: 181.5°C
• Appearance: /
• Density: 1.198g/cm³
• Vapor Pressure: 3.34E-06mmHg at 25°C
• Refractive Index: 1.537
• CAS DataBase Reference: 2',4'-DIFLUORO-3-(2-METHOXYPHENYL)PROPIOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2',4'-DIFLUORO-3-(2-METHOXYPHENYL)PROPIOPHENONE(898774-10-2)
• EPA Substance Registry System: 2',4'-DIFLUORO-3-(2-METHOXYPHENYL)PROPIOPHENONE(898774-10-2)

Safety Data

• Hazardous Substances Data: 898774-10-2(Hazardous Substances Data)

Usage

Class

Organic compound

Odor

Pleasant

Functional groups

Two fluorine atoms, a methoxyphenyl group

Uses

Organic synthesis, pharmaceutical research, medicinal chemistry, drug discovery and development

Versatility

Valuable chemical compound with a range of potential uses in various industries.

InChI:InChI=1/C16H14F2O2/c1-20-16-5-3-2-4-11(16)6-9-15(19)13-8-7-12(17)10-14(13)18/h2-5,7-8,10H,6,9H2,1H3

Upstream product

• 135-02-4 ortho-anisaldehyde 
• 364-83-0 2',4'-difluoroacetophenone 

Relevant articles and documents

2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5

In our previous work, novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were synthesized, and their activities were evaluated against HIV-1 reverse transcriptase. Some interesting results were obtained, which led us to a new discovery regarding these TSTs. In the present study, 21 new 2,4,5-trisubstituted thiazole derivatives were rationally designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in accordance with our previous study. Among the synthesized target compounds, compounds 14, 16, 17, and 19 showed more potent inhibitory activities against HIV-1 with an IC50value of 0.010?μM. Compounds 4, 9, 10, 11, 13 and 16 were further tested on nine NNRTI-resistant HIV-1 strains, and all of these compounds exhibited inhibitory effects. A molecular docking study was conducted, and the results showed a consistent and stable binding mode for the typical compounds. These results have provided deeper insights and SAR of these types of NNRTIs.